Responding to a rise in new, often fatal infectious agents in healthcare and other public settings, Lonza’s Hygiene & Preservation business has now gained US EPA approval for several of its disinfectant formulations: the Lonzagard R82 family of products. Wipes Plus disinfectant wipes and Plus 2 disinfectant wipes have been approved to combat the dangerous new avian influenza A (H7N9) virus and Candida Albicans, a bloodstream infection prevalent in hospitals, on hard nonporous surfaces.
Avian influenza A (H7N9) virus human infections were first reported in China in March 2013 and have now spread beyond its borders, according to the US Centers for Disease Control.
“With these new EPA approvals, we can offer our customers what they need most: powerful, fast-acting disinfectants that combat the broadest possible array of deadly pathogens on hard nonporous surfaces,” said Ray Fahmy, business director for Lonza Hygiene & Preservation North America.
More info: www.lonzabiocides.com